CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma

BACKGROUND: In clinical applications of CAR T-cell therapy, life-threatening adverse events including cytokine release syndrome and neurotoxicity can lead to treatment failure. Outcomes of patients treated with anti-CD30 CAR T- cell have been disappointing in relapsing/refractory (r/r) classical Hod...

Descripción completa

Detalles Bibliográficos
Autores principales: Xue, YuanBo, Lai, Xun, Li, RuiLei, Ge, ChunLei, Zeng, BaoZhen, Li, Zhen, Fu, QiaoFen, Zhao, LiuFang, Dong, SuWei, Yang, JinYan, Guo, JiYin, Meng, QingYin, Tan, QingHua, Li, ZhenHui, Ding, HaiYan, Zhang, YanLei, Liu, ShaoHui, Chang, Alex H., Yao, Hong, Luo, RongCheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885818/
https://www.ncbi.nlm.nih.gov/pubmed/33604290
http://dx.doi.org/10.3389/fonc.2020.607362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7885818/
https://www.ncbi.nlm.nih.gov/pubmed/33604290
http://dx.doi.org/10.3389/fonc.2020.607362

Ejemplares similares